🇺🇸 Levothyroxin-Na in United States
2 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 2
Most-reported reactions
- Headache — 1 report (50%)
- Intentional Product Misuse — 1 report (50%)
Other Endocrinology approved in United States
Frequently asked questions
Is Levothyroxin-Na approved in United States?
Levothyroxin-Na does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Levothyroxin-Na in United States?
Sanofi is the originator. The local marketing authorisation holder may differ — check the official source linked above.